Skip to main
ELAN

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 63%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health demonstrates strong market positioning with its Simparica Trio maintaining over a 50% market share, indicating robust competitiveness in the companion animal sector. Additionally, the anticipated growth of Credelio Quattro, projected to rise to 16.8% market share by 2026, further underscores the company’s growth trajectory in the animal health market. Furthermore, significant year-over-year sales increases in key product lines, such as the Advantage Family and Seresto, which have recorded 33% and 28% growth respectively, reflect sustained demand and operational momentum.

Bears say

Elanco Animal Health is facing challenges regarding its refinancing strategy, which may pose a near-term risk to earnings growth in 2026, particularly in light of rising interest rates reflected by a recent $550MM offering by Dentsply Sirona at 8.375%. Despite a 50% increase in revenue, the company has experienced a decline in EBITDA margin by a couple of hundred basis points, indicating potential inefficiencies or rising costs that could impact profitability. Additionally, while Elanco reported a $28MM EBITDA outperformance in the second quarter, the overall financial metrics suggest underlying weaknesses that could hinder future growth prospects.

ELAN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 63% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 8 analysts, ELAN has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.